CN105517547A - 吡咯并吡咯氨基甲酸酯和相关的有机化合物、药物组合物及其医学用途 - Google Patents

吡咯并吡咯氨基甲酸酯和相关的有机化合物、药物组合物及其医学用途 Download PDF

Info

Publication number
CN105517547A
CN105517547A CN201480048531.6A CN201480048531A CN105517547A CN 105517547 A CN105517547 A CN 105517547A CN 201480048531 A CN201480048531 A CN 201480048531A CN 105517547 A CN105517547 A CN 105517547A
Authority
CN
China
Prior art keywords
pyrrole
methyl
carboxylate
octahydropyrrolo
hexafluoropropan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480048531.6A
Other languages
English (en)
Chinese (zh)
Inventor
托德·K·琼斯
贾斯汀·S·奇萨
谢丽尔·A·格莱斯
东-辉·王
奥利维亚·D·韦伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lundbeck La Jolla Research Center Inc
Original Assignee
Abide Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abide Therapeutics Inc filed Critical Abide Therapeutics Inc
Publication of CN105517547A publication Critical patent/CN105517547A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201480048531.6A 2013-07-03 2014-07-01 吡咯并吡咯氨基甲酸酯和相关的有机化合物、药物组合物及其医学用途 Pending CN105517547A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361842543P 2013-07-03 2013-07-03
US61/842,543 2013-07-03
PCT/US2014/045145 WO2015003002A1 (en) 2013-07-03 2014-07-01 Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof

Publications (1)

Publication Number Publication Date
CN105517547A true CN105517547A (zh) 2016-04-20

Family

ID=52144176

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480048531.6A Pending CN105517547A (zh) 2013-07-03 2014-07-01 吡咯并吡咯氨基甲酸酯和相关的有机化合物、药物组合物及其医学用途

Country Status (7)

Country Link
US (1) US9828379B2 (https=)
EP (1) EP3016653A4 (https=)
JP (1) JP6647592B2 (https=)
CN (1) CN105517547A (https=)
CA (1) CA2917050A1 (https=)
MX (1) MX2015017961A (https=)
WO (1) WO2015003002A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996790A (zh) * 2016-09-19 2019-07-09 阿比德治疗公司 哌嗪氨基甲酸酯及其制备和使用方法
CN110267962A (zh) * 2016-11-16 2019-09-20 灵北拉荷亚研究中心公司 Magl抑制剂
CN110290791A (zh) * 2016-11-16 2019-09-27 灵北拉荷亚研究中心公司 药物制剂
CN110382479A (zh) * 2017-01-20 2019-10-25 辉瑞大药厂 作为magl抑制剂的氨基甲酸1,1,1-三氟-3-羟基丙-2-基酯衍生物
CN111148746A (zh) * 2017-09-29 2020-05-12 武田药品工业株式会社 杂环化合物
US11993588B2 (en) 2016-11-16 2024-05-28 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20141702A1 (es) 2012-01-06 2014-11-19 Abide Therapeutics Inc Compuestos de carbamato y preparacion y uso de los mismos
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター，インク． ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用
TN2017000544A1 (en) * 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
US10781211B2 (en) 2016-05-12 2020-09-22 Lundbeck La Jolla Research Center, Inc. Spirocycle compounds and methods of making and using same
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
NZ797702A (en) * 2017-03-13 2026-03-27 Lundbeck La Jolla Research Center Inc Dual magl and faah inhibitors
JP7257387B2 (ja) 2017-08-29 2023-04-13 ハー・ルンドベック・アクチエゼルスカベット スピロ環化合物並びにその作製及び使用方法
CN111032034B (zh) * 2017-08-29 2023-05-02 H.隆德贝克有限公司 螺环化合物及其制造和使用方法
GEP20227443B (en) 2018-05-15 2022-11-25 H Lundbeck As Magl inhibitors
MX2021000549A (es) * 2018-07-19 2021-03-25 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
WO2021062232A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for reducing rewarding effects of morphine without affecting its analgesic effects
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
TWI904281B (zh) 2020-11-13 2025-11-11 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
EP4317153A4 (en) * 2021-04-01 2024-02-21 ONO Pharmaceutical Co., Ltd. Abhd6 antagonist
CA3242372A1 (en) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibiting monoacylglycerol lipase (magl)
KR20250005229A (ko) 2022-05-04 2025-01-09 하. 룬드벡 아크티에셀스카브 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012052730A1 (en) * 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Use of pi3k inibitors for the treatment of obesity, steatosis and ageing
US20120208812A1 (en) * 2009-10-23 2012-08-16 Janssen Pharmaceutica N.V. DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
CA2440803A1 (en) * 2001-03-07 2002-09-12 Pfizer Products Inc. Modulators of chemokine receptor activity
JP2011513421A (ja) 2008-03-05 2011-04-28 ターガセプト，インコーポレイテッド サブタイプ選択的なジアザビシクロアルカンのアミド
WO2011109277A1 (en) * 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
KR102179599B1 (ko) 2012-09-25 2020-11-19 에프. 호프만-라 로슈 아게 이환형 유도체
JP6647592B2 (ja) 2013-07-03 2020-02-14 ルンドベック ラ ホーヤ リサーチ センター，インク． ピロロピロールカルバメート、および関連する有機化合物、医薬組成物、ならびにその医学的使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208812A1 (en) * 2009-10-23 2012-08-16 Janssen Pharmaceutica N.V. DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS
WO2012052730A1 (en) * 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Use of pi3k inibitors for the treatment of obesity, steatosis and ageing

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996790A (zh) * 2016-09-19 2019-07-09 阿比德治疗公司 哌嗪氨基甲酸酯及其制备和使用方法
CN109996790B (zh) * 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
CN110267962A (zh) * 2016-11-16 2019-09-20 灵北拉荷亚研究中心公司 Magl抑制剂
CN110290791A (zh) * 2016-11-16 2019-09-27 灵北拉荷亚研究中心公司 药物制剂
CN110267962B (zh) * 2016-11-16 2022-04-01 H.隆德贝克有限公司 Magl抑制剂
US11993588B2 (en) 2016-11-16 2024-05-28 H. Lundbeck A/S Crystalline forms of a MAGL inhibitor
CN110382479A (zh) * 2017-01-20 2019-10-25 辉瑞大药厂 作为magl抑制剂的氨基甲酸1,1,1-三氟-3-羟基丙-2-基酯衍生物
CN111148746A (zh) * 2017-09-29 2020-05-12 武田药品工业株式会社 杂环化合物
US11274101B2 (en) 2017-09-29 2022-03-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN111148746B (zh) * 2017-09-29 2022-08-05 武田药品工业株式会社 杂环化合物

Also Published As

Publication number Publication date
WO2015003002A1 (en) 2015-01-08
MX2015017961A (es) 2016-10-14
US20160137649A1 (en) 2016-05-19
JP6647592B2 (ja) 2020-02-14
EP3016653A4 (en) 2017-02-22
US9828379B2 (en) 2017-11-28
JP2016525092A (ja) 2016-08-22
EP3016653A1 (en) 2016-05-11
CA2917050A1 (en) 2015-01-08

Similar Documents

Publication Publication Date Title
CN105517547A (zh) 吡咯并吡咯氨基甲酸酯和相关的有机化合物、药物组合物及其医学用途
CN107660199B (zh) 哌嗪氨基甲酸酯及其制备和使用方法
JP7177825B2 (ja) スピロ環化合物並びにその作製及び使用方法
JP7162622B2 (ja) ピラゾールｍａｇｌ阻害剤
EP3377060B1 (en) Pyrazole derivatives, processes for their preparation and uses thereof
CN111050765B (zh) 螺环化合物及其制造和使用方法
CN109996790B (zh) 哌嗪氨基甲酸酯及其制备和使用方法
AU2018271876B2 (en) Pyrazole MAGL inhibitors
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
EP3455226B1 (en) Spirocycle compounds and methods of making and using same
CN116981675A (zh) 通过布鲁顿氏酪氨酸激酶（btk）抑制剂与e3连接酶配体的缀合降解btk和使用方法
IL297867B1 (en) New macrocyclic lrrk2 kinase inhibitors
EP4161656A1 (en) Inhibitors of fibroblast growth factor receptor kinases
CN116783199A (zh) 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物
CN115698020B (zh) 大环rip2-激酶抑制剂
EP3400226A1 (en) Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
TW202428267A (zh) 用於降解ｅｇｆｒ激酶之化合物
CN110655520A (zh) 嘧啶并环化合物及其制备方法和应用
JP2023505485A (ja) Ａｔｍキナーゼ阻害剤及び組成物並びにそれらの使用の方法
AU2021267691B2 (en) New Macrocyclic LRRK2 kinase inhibitors
EA048670B1 (ru) Макроциклические ингибиторы lrrk2 киназы
HK40004417A (en) Spirocycle compounds and methods of making and using same
HK1256634B (en) Pyrazole compounds and methods of making and using same
HK1234388A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 an methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160420

WD01 Invention patent application deemed withdrawn after publication